Peanut Allergy Treatment

View All

peanut-allergy-market-size-share-trends-prevalence-therapies-therapeutics-drugs
Peanut Allergy Market Outlook: The Market Size Growth Sees Major Thrusts

Peanut allergy (PA) is one of the most common food allergies that affect children in Western nations. It is diagnosed at early stages and often persists till adulthood in approximately 75%–80% of the cases.  DelveInsight estimates that approximately 10,578,543 Peanut allergy prevalent cases were reported in 7M...

Find More

Pharma News
First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares

The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set to address the unmet needs in the Peanut market, reducing the incidence and severity of allergic reactions, including anaphylaxis, which may ...

Find More